Quoin Pharma Establishes Japan Subsidiary for QRX003 Commercialization

Quoin Pharmaceuticals announced the establishment of a wholly-owned subsidiary in Japan to directly commercialize QRX003 for Netherton Syndrome, if approved. This move follows the recent grant of Orphan Drug Designation for QRX003 by Japan's Ministry of Health, Labour and Welfare, reinforcing Quoin's long-term commercial strategy in one of its three core markets. The new local presence will facilitate direct engagement with Japanese regulators, clinicians, and patient advocacy groups as the company builds its commercial infrastructure ahead of a potential launch. QRX003 has now secured Orphan Drug Designation in the United States, the European Union, and Japan, providing significant development and commercial incentives.